Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Soc Gynecol Investig ; 12(4): 278-84, 2005 May.
Artigo em Inglês | MEDLINE | ID: mdl-15866121

RESUMO

OBJECTIVE: Loss of expression of progesterone receptors (PR) in endometrial cancer is related to a more invasive and metastatic phenotype. In this study we aim to investigate whether selective loss of PRA or PRB affects the invasive capacity of endometrial cancer cells. METHODS: cDNA microarrays were performed to compare gene expression profiles of a set of endometrial cancer sub-cell lines expressing PRA and/or PRB. In vitro invasion assays were performed to assess whether differences in gene expression between the lines were reflected by their invasive behavior. RESULTS: It was observed that cell lines that express only PRA express higher levels of cadherins, and show a lower level of invasion compared to cell lines that express PRB. When cadherin function was inhibited in exclusively PRA-expressing cell lines, an increase of in vitro invasion was observed. In support of these findings, it was observed that in higher grade and more invasive endometrial cancer, expression of E-cadherin decreased. CONCLUSIONS: These results indicate that relative loss of PRA during progression of endometrial cancer can have a negative impact on cadherin expression, which may lead to development of a more metastatic phenotype.


Assuntos
Neoplasias do Endométrio/patologia , Invasividade Neoplásica/genética , Invasividade Neoplásica/fisiopatologia , Receptores de Progesterona/biossíntese , Western Blotting , Caderinas/biossíntese , Feminino , Perfilação da Expressão Gênica , Humanos , Imuno-Histoquímica , Metástase Neoplásica , Análise de Sequência com Séries de Oligonucleotídeos , Fenótipo , Células Tumorais Cultivadas
2.
Clin Cancer Res ; 9(11): 4190-9, 2003 Sep 15.
Artigo em Inglês | MEDLINE | ID: mdl-14519645

RESUMO

PURPOSE: In endometrial cancer, loss of progesterone receptors (PR) is associated with more advanced disease. This study aimed to investigate the mechanism of action of progesterone and the loss of its receptors (PRA and PRB) in development of endometrial cancer. EXPERIMENTAL DESIGN: A 9600-cDNA microarray analysis was performed to study regulation of gene expression in the human endometrial cancer subcell line Ishikawa PRAB-36 by the progestagen medroxy progesterone acetate (MPA). Five MPA-regulated genes were selected for additional investigation. Expression of these genes was studied by Northern blot and by immunohistochemistry in Ishikawa subcell lines expressing different PR isoforms. Additionally, endometrial cancer tissue samples were immunohistochemically stained to study the in vivo protein expression of the selected genes. RESULTS: In the PRAB-36 cell line, MPA was found to regulate the expression of a number of invasion- and metastasis-related genes. On additional investigation of five of these genes (CD44, CSPG/Versican, Tenascin-C, Fibronectin-1, and Integrin-beta 1), it was observed that expression and progesterone regulation of expression of these genes varied in subcell lines expressing different PR isoforms. Furthermore, in advanced endometrial cancer, it was shown that loss of expression of both PR and E-cadherin was associated with increased expression CD44 and CSPG/Versican. CONCLUSION: The present study shows that progestagens exert a modulatory effect on the expression of genes involved in tumor cell invasion. As a consequence, loss of PR expression in human endometrial cancer may lead to development of a more invasive phenotype of the respective tumor.


Assuntos
Neoplasias do Endométrio/genética , Neoplasias do Endométrio/patologia , Regulação Neoplásica da Expressão Gênica/genética , Receptores de Progesterona/genética , Adenocarcinoma/genética , Adenocarcinoma/patologia , Linhagem Celular Tumoral , Proteoglicanas de Sulfatos de Condroitina/genética , Feminino , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Humanos , Receptores de Hialuronatos/genética , Lectinas Tipo C , Acetato de Medroxiprogesterona/farmacologia , Invasividade Neoplásica/genética , Proteínas de Neoplasias/genética , Tenascina/genética , Versicanas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA